Publications by authors named "Ryan Huss"

Claim this Profile
I
Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASH.
Jake Conway, Maryam Pouryahya, Yevgeniy Gindin, David Z Pan, Oscar M Carrasco-Zevallos, Ryan S Huss

Cell Rep Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate.
Mohamad Dandan, Julia Han, Sabrina Mann, Rachael Kim, Kelvin Li, Hussein Mohammed, Ryan S Huss

J Lipid Res· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.
Rohit Loomba, Daniel Q Huang, Arun J Sanyal, Quentin Mark Anstee, Michael Trauner, Ryan S Huss

Gut· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
Arun J Sanyal, Julie Foucquier, Zobair M Younossi, Stephen A Harrison, Philip N Newsome, Ryan S Huss

J Hepatol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat.
Eric J Lawitz, Bal Raj Bhandari, Peter J Ruane, Anita Kohli, Eliza Harting, Ryan S Huss

Clin Gastroenterol Hepatol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen-Chieh Chuang, Ryan S Huss

Hepatology· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
Ekaterina Smirnova, Mark D Muthiah, Nicole Narayan, Mohamad S Siddiqui, Puneet Puri, Ryan S Huss

Hepatology· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
Naim Alkhouri, Robert Herring, Heidi Kabler, Zeid Kayali, Tarek Hassanein, Ryan S Huss

J Hepatol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients.
Eric J Lawitz, Kelvin W Li, Edna Nyangau, Tyler John Field, Jen-Chieh Chuang, Ryan S Huss

J Lipid Res· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automated CNN-Based Analysis Versus Manual Analysis for MR Elastography in Nonalcoholic Fatty Liver Disease: Intermethod Agreement and Fibrosis Stage Discriminative Performance.
Guilherme M Cunha, Timoteo I Delgado, Michael S Middleton, Sam Liew, Walter C Henderson, Ryan S Huss

AJR Am J Roentgenol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.
Arun J Sanyal, Quentin M Anstee, Michael Trauner, Eric J Lawitz, Manal F Abdelmalek, Ryan S Huss

Hepatology· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.
Amaro Taylor-Weiner, Harsha Pokkalla, Ling Han, Catherine Jia, Ryan Huss

Hepatology· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
Zobair M Younossi, Maria Stepanova, Mazen Noureddin, Kris V Kowdley, Simone I Strasser, Ryan S Huss

Hepatol Commun· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Rohit Loomba, Mazen Noureddin, Kris V Kowdley, Anita Kohli, Aasim Sheikh, Ryan S Huss

Hepatology· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synovial tissue-infiltrating natural killer cells in osteoarthritis and periprosthetic inflammation.
Ryan S Huss, James I Huddleston, Stuart B Goodman, Eugene C Butcher, Brian A Zabel

Arthritis Rheum· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis